10/03/2026 16:28
|
Medical, Health & Aged Care
Australian Pharmaceutical company Phebra (‘Company’) has announced the launch of Rapiblyk® (landiolol hydrochloride), an ultra‑short‑acting, cardio-selective receptor antagonist, indicated for...